ClinicalTrials.gg
CompletedNCT07545590Updated Oct 6, 2026

A Study of Eltrekibart (LY3041658) in Healthy Participants

A Phase 1 interventional study of LY3041658 and LY3041658 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Oct 6, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants.

The study will last about 17 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history and physical examination
  • Have a minimum body weight of 45 kilograms (kg).
  • Have a (BMI) within the range of 18.5 to 28.5 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

Exclusion Criteria:

  • Have multiple severe allergies to prescription or nonprescription drugs
  • Are
  • Have had any of the following types of infection within 3 months prior to the screening visit:

    • Serious, that is, requiring hospitalization, or intravenous or equivalent oral antibiotic treatment
    • Opportunistic infections Note: Herpes zoster is considered active and ongoing until all vesicles are dry and crusted over
    • Chronic, that is, duration of symptoms, signs, or treatment of 6 weeks or longer, or
    • Recurring, including, but not limited to:

      • herpes simplex,
      • herpes zoster,
      • recurring cellulitis, or
      • chronic osteomyelitis.
  • Are currently pregnant or are intending to become pregnant or to breastfeed at any time in the study or within 16 weeks after receiving the single dose of study intervention.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Eltrekibart Cohort 1

    Eltrekibart administered subcutaneously (SC)

    Drug: LY3041658

  • Experimental
    Eltrekibart Cohort 2

    Eltrekibart administered SC

    Drug: LY3041658

  • Experimental
    Eltrekibart Cohort 3

    Eltrekibart administered intravenously (IV)

    Drug: LY3041658

  • Experimental
    Eltrekibart Cohort 4

    Eltrekibart administered SC

    Drug: LY3041658

Interventions

  • Administered SC

    Also known as: Eltrekibart

  • Administered IV

    Also known as: Eltrekibart

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658

    Time frame: Predose on Day 1 up to Day 85

  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3041658

    Time frame: Predose on Day 1 up to Day 85

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration AUC(0-tlast) of LY3041658

    Time frame: Predose on Day 1 up to Day 85

07

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Sep 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 22, 2026
StartActual
Apr 21, 2026
Primary completionActual
Sep 22, 2026
CompletionActual
Sep 22, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07545590
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 21, 2026
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrekibart

Start the discussion